Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.855 USD | -1.33% | +3.63% | -12.91% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.91% | 284M | |
+1.97% | 42.59B | |
+8.10% | 40.65B | |
+49.22% | 40.57B | |
-11.96% | 26.77B | |
+9.13% | 24.81B | |
-24.28% | 18.17B | |
+27.24% | 12.05B | |
-3.39% | 11.7B | |
+6.92% | 11.1B |
- Stock Market
- Equities
- ERAS Stock
- News Erasca, Inc.
- Erasca Gets FDA Clearance for ERAS-3490 Cancer Therapy Trial